Alyeska Investment Group
AUPH icon

Alyeska Investment Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

Alyeska Investment Group’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-188,709
Closed -$1.06M – 408
2018
Q2 		$1.06M Sell
188,709
-387,615
-67% -$2.16M 0.01% 394
2018
Q1 		$2.99M Sell
576,324
-5,193
-0.9% -$27.8K 0.02% 323
2017
Q4 		$2.63M Sell
581,517
-100,000
-15% -$555K 0.02% 312
2017
Q3 		$4.27M Buy
681,517
+12,171
+2% +$76.7K 0.03% 303
2017
Q2 		$4.1M Sell
669,346
-120,846
-15% -$814K 0.03% 295
2017
Q1 		$5.8M Buy
+790,192
New +$3.65M 0.05% 299

Other funds holding AUPH

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Alyeska Investment Group's AUPH Position: Q3 2018 in Review

Alyeska Investment Group sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2018, closing a stake of 188,709 shares — an estimated $1.06M sold.

Alyeska Investment Group first reported a position in AUPH in Q1 2017 and held it in 6 quarters. The position peaked at $5.8M in Q1 2017. 63 funds tracked by Wall St. Rank hold AUPH as of Q3 2018.

  • Alyeska Investment Group reported no remaining Aurinia Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 188,709 Aurinia Pharmaceuticals shares in Q3 2018, an estimated $1.06M.
  • Alyeska Investment Group first reported a position in Aurinia Pharmaceuticals in Q1 2017 and held it in 6 quarters.
  • Alyeska Investment Group's Aurinia Pharmaceuticals position peaked at $5.8M in Q1 2017.
  • 63 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2018.

Based on Alyeska Investment Group's 13F filing for Q3 2018, filed 14 Nov 2018.